The Insight Partners published latest research report on “Neoantigens Market Analysis Report, Size, Share, Trends, Growth & Demand Forecast to 2028 - COVID-19 Impact and Global Analysis By Treatment and Therapeutic Specialty”,
The Insight Partners published latest research report on "Neoantigens Market Analysis Report, Size, Share, Trends, Growth & Demand Forecast to 2028 - COVID-19 Impact and Global Analysis By Treatment and Therapeutic Specialty”, the global market share is projected to reach USD 10,54,783.54 thousand by 2028 from USD 2,71,428.57 thousand in 2023; it is estimated to grow at a CAGR of 31.2% from 2023 to 2028.
Request Sample PDF Brochure: https://www.theinsightpartners.com/sample/TIPRE00021781
Growth Strategies by the Key Players Operating in the Neoantigens Market:
Apr-2021: Immunicum has announced the start of a research partnership with Nina Bhardwaj's laboratory at the Tisch Cancer Institute's Icahn School of Medicine at Mount Sinai in New York City. Bhardwaj is the Director of Immunotherapy and Medical Director of the Vaccine and Cell Therapy Core Facility.
Apr-2020: Frame Therapeutics and eTheRNA immunotherapies NV have established a new research partnership to create mRNA cancer vaccines against immunogenic neoantigens.
May-2019: Ziopharm announced an exclusive licence arrangement with the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), for intellectual property relating to the production and commercialization of cancer cell therapies.
Neoantigens are recently developed antigens that have not been detected by the immune system historically. Alterations in tumor proteins may result in the development of neoantigens caused by mutations or viral proteins. Neoantigens are used in selective treatments for cancerous cells.
Many biotechnology companies are involved in the development of neoantigens, and most of them are in the clinical and pre-clinical phases of development. As per the data obtained from ClinicalTrials.gov, many clinical studies have been completed and moved on to the next stage of clinical trials in the US and other countries. For instance, Phase 1 study of ADXS-NEO is an antigen delivery product developed by Advaxis to identify neoantigens is under Phase 1 of clinical trials. Furthermore, Genocea Biosciences, Inc. is evaluating a personalized adjuvant vaccine, GEN-009 Neoantigen Vaccine, for the treatment of patients with solid tumors. Currently, the candidate is in a Phase 1/2a clinical trial. With the assumption of the probable commercial availability of neoantigen for clinical treatment in 2023. Analyzing this, the market has been forecasted from 2023 to 2028.
Directly Purchase Premium Copy of Neoantigens Market Growth Report (2023-2028) at: https://www.theinsightpartners.com/buy/TIPRE00021781/
Global Neoantigens Market Share Report, Segmentations, Regional & Country Scope:
|
Report Coverage |
Details |
|
Market Size Value in |
USD 2,71,428.57 thousand in 2023 |
|
Market Size Value by |
USD 10,54,783.54 thousand by 2028 |
|
Growth rate |
CAGR of 31.2% from 2023-2028 |
|
Forecast Period |
2023-2028 |
|
Base Year |
2023 |
|
No. of Pages |
151 |
|
No. of Tables |
61 |
|
No. of Charts & Figures |
69 |
|
Historical data available |
Yes |
|
Segments covered |
Treatment and Therapeutic Specialty |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
|
Country scope |
US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina |
|
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
|
Companies Covered |
Achilles Therapeutics plc, Advaxis, Inc., Frame Cancer Therapeutics, Genocea, Gradalis, Inc., Gritstone Oncology, Immunicum AB, Medigene AG, Ziopharm Oncology, Inc., Moderna, Inc. |
|
Key Research Capabilities |
Global Market Assessment, Business Development Strategies, Competitive Landscape, Opportunity Analysis, Regional and Country Level Market Analysis, Market Entry Strategies, Market Dynamics, Risk and Return Assessments, Pricing Analysis, Market Size and Forecasting, Company Profiling, Value Chain Analysis, Expansion Strategies, SWOT Analysis, New Product Development |
Browse key market insights spread across 151 pages with 61 list of tables & 69 list of figures from the report, "Neoantigens Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Treatment (Combination Therapy and Mono Therapy) and Therapeutic Specialty (Gastrointestinal Cancer, Lung Cancer, Solid Tumor, Urinary Systems Cancers, Melanoma, Head and Neck Cancer, and Others)" in detail along with the table of contents: https://www.theinsightpartners.com/reports/neoantigens-market
Private organizations and companies as well as government associations are equally participating in the development of immunotherapy methods by integrating IT with life sciences. Healthcare IT and neoantigen market players are integrating artificial intelligence (AI) technology with neoantigens to identify patient-specific immunogenic cancer mutations. In May 2020, NEC Corporation, an IT and network technologies company, and Transgene, a company involved in the development of virus-based immunotherapies for cancer treatment, announced to publish their findings in the upcoming American Association for Cancer Research (AACR) Annual Meeting 2020 (AACR Virtual Annual Meeting II) in June 2020. The companies were looking forward to announcing data related to a prediction algorithm that can be used to customize an individualized therapeutic vaccine TG4050 for patients as per their immunogenic cancer mutation is accurate in June 2020 at AACR Virtual Annual Meeting II. The customization of TG4050 would be more specific, and it would be possible for a large set of candidate mutations. The TG4050 was designed by using the myvac technology of Transgene and Neoantigen Prediction System of NEC. The prediction system is an advanced AI technology that has been in use in the field of oncology. The TG4050 is developed to treat solid tumors and is currently in the Phase 1 clinical trial in the US and Europe. Thus, the integration of AI with neoantigen vaccine research is emerging as a key trend in the neoantigen market.
The increasing prevalence of cancer has created burden on the healthcare systems across the world. According to International Agency for Research on Cancer (IARC), the global burden of new cancer cases is estimated to reach ~ 27.5 million by 2040, and the disease likely to be a cause of ~163 million deaths by that year. Factors such as lifestyle changes, smoking, reduced physical activities, and uncertain health and climatic conditions are likely to lead to even greater burden of cancer in the world in the coming years. Therefore, it is essential to control and prevent the increasing number of cancers worldwide.
Various governments have initiated programs and initiative to increase the treatment and preventive measures for cancers. For instance, in 2017, World Health Assembly has approved the Resolution Cancer (WHA70.12), an integrated approach to prevent and control cancer. The program has been appealing the WHO and various governments to accelerate their efforts to achieve the targets that are specified in the Global Action Plan (2013–2020) for the prevention and control of noncommunicable diseases (NCDs) as well as in the 2030 UN Agenda for Sustainable Development to reduce early deaths from cancer. In addition, various private organizations have joined the action plans to prevent the increasing burden of cancer, which is creating a demand for better preventive measures against the disease. Thus, the increasing prevalence of cancer have accelerated the demand for new and effective therapeutic approaches such as neoantigens, which is boosting the growth of market.
Major primary and secondary sources referred to while preparing the report on the neoantigens market are American Association for Cancer Research, Cancer Association of South Africa, European Medicines Agency, The Food and Drug Administration, Institute for Research in Immunology and Cancer – Commercialization of Research, and the World Health Organization, among others.
Go through further research published by The Insight Partners: (Purchase with 10% Instant Discount):
Cancer Antigen Market Forecast to 2028 - COVID-19 Impact and Global Analysis
Bacterial Antigens Market Forecast to 2028 - COVID-19 Impact and Global Analysis
Viral Antigens Market Forecast to 2027 - COVID-19 Impact and Global Analysis
Native Bacterial Antigens Market Forecast to 2028 - COVID-19 Impact and Global Analysis
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876
Press Release: https://www.theinsightpartners.com/pr/neoantigens-market